Shares of Legend Biotech Corporation ( LEGN - Free Report ) rose 14.2% on Oct 18 after management announced preliminary sales figures for its multiple myeloma therapy, Carvykti (ciltacabtagene autoleucel), for third-quarter 2022. The therapy has been developed in partnership with J&J ( JNJ - Free Report ).